BGB324 (BerGenBio); also known as R428 (Rigel Pharmaceuticals), is an oral selective small molecule AXL inhibitor that is currently being investigated in phase II clinical trials of pancreatic neoplasms (Table 2). Here, AXL is linked to pancreatic neoplasm.